Scientific publications

Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma

Wang M (1), Rule S (2), Zinzani PL (3), Goy A (4), Casasnovas O (5), Smith SD (6), Damaj G (7), Doorduijn JK (8), Lamy T (9), Morschhauser F (10), Panizo C (11), Shah B (12), Davies A (13), Eek R (14), Dupuis J (15), Jacobsen E 16, Kater AP (17), Le Gouill S (18), Oberic L (19), Robak T (20), Jain P (21), Frigault MM (22), Izumi R (22), Nguyen D (22), Patel P (22), Yin M (22), Długosz-Danecka M (2)3.

(1) MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
(2) Plymouth University Medical School, Plymouth, UK.
(3) Institute of Hematology "Seràgnoli", University of Bologna, Bologna, Italy.
(4) John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
(5) CHU Dijon - Hôpital d'Enfants, Dijon, France.
(6) Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
(7) Institut d'Hématologie de Basse-Normandie, Caen, France.
(8) Erasmus MC, HOVON Lunenburg Lymphoma Phase I/II Consortium, Rotterdam, Netherlands.
(9) CHU de Rennes, Rennes, France.
(10) Univ. Lille, CHU Lille, EA 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, F-59000, Lille, France.
(11) Clínica Universidad de Navarra, Pamplona, Spain.
(1)2 Moffitt Cancer Center, Tampa, FL, USA.
(13) Cancer Research UK Centre, University of Southampton Faculty of Medicine, Southampton, UK.
(14) Border Medical Oncology, Albury, Victoria, Australia.
(15) Unité Hémopathies Lymphoïdes, AP-HP Hôpital Henri Mondor, Créteil, France.
(16) Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
(17) Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, HOVON Lunenburg Lymphoma Phase I/II Consortium, Amsterdam, Netherlands.
(18) CHU de Nantes-Hotel Dieu, Nantes, France.
(19) Institut Universitaire du Cancer-Oncopole Toulouse (IUCT-O), Toulouse, France.
(20) Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland.
(21) MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
(22) Acerta Pharma, South San Francisco, CA, USA.
(23) Department of Haematology, Jagiellonian University, Krakow, Poland.

Magazine: Leukemia

Date: Sep 26, 2019

Hematología y Hemoterapia [SP]

Bruton tyrosine kinase (BTK) inhibitors have greatly improved the spectrum of treatment options in mantle cell lymphoma (MCL) [1,2,3,4]. Acalabrutinib is a highly selective, orally administered, and potent BTK inhibitor with limited off-target activity [5]. Acalabrutinib was approved in 2017 by the US Food and Drug Administration for the treatment of relapsed/refractory MCL based on clinical data from the open-label, multicenter, phase 2 ACE-LY-004 study of acalabrutinib 100 mg twice daily [1]. Here, we present updated results from the ACE-LY-004 study after a median 26-month follow-up.

CITATION  Leukemia. 2019 Sep 26. doi: 10.1038/s41375-019-0575-9. 



The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra


The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra


Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra